Table 2.
Biomarker data of the study cohort
| Variables | Whole cohort (n = 188) | SCD (n = 89) | MCI (n = 99) | Significance |
|---|---|---|---|---|
| A + status | 53 (28.19%) | 28 (31.46%) | 25 (25.25%) | 0.434 b |
| Brain MRI | ||||
| Fazekas category 2–3 | 20 (10.64%) | 13 (14.61%) | 7 (7.07%) | 0.151 b |
| WMH volume (mm3) | 3203.91 ± 4506.54 | 3408.14 ± 4752.04 | 3020.31 ± 4289.90 | 0.559 a |
| OCT-A | ||||
| VD nasal | 47.66 ± 3.81 | 47.03 ± 3.16 | 48.23 ± 4.24 | 0.028* a |
| VD superior | 48.67 ± 4.74 | 48.11 ± 4.18 | 49.17 ± 5.16 | 0.124 a |
| VD temporal | 45.83 ± 3.42 | 44.97 ± 2.94 | 46.59 ± 3.65 | 0.001* a |
| VD inferior | 47.81 ± 5.44 | 46.89 ± 4.40 | 48.65 ± 6.14 | 0.024* a |
Data are shown as mean ± standard deviation for quantitative variables and n (%) for qualitative variables
A + status was defined as FBB-PET Centiloid > 13.5 in the FACEHBI study and CSF Aβ42/Aβ40 ratio < 0.063 in the BIOFACE study
Abbreviations: A Amyloid, MCI Mild cognitive impairment, MRI Magnetic resonance imaging, OCT-A Optical coherence tomography – angiography, SCD Subjective cognitive decline, VD Vessel density, WMH White matter hyperintensity
*Significance was set up at p < 0.05
aStudent’s t test; bPearson’s chi-square test